Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

Elias Jabbour, Hagop Kantarjian, Susan O'Brien, Tapan Kadia, Asifa Malik, Mary Alma Welch, Angela Teng, Jorge Cortes, Farhad Ravandi, Guillermo Garcia-Manero

Research output: Contribution to journalArticle

5 Scopus citations


Background: After the World Health Organization (WHO) changed the definition of acute myeloid leukemia (AML) to ≥ 20% blasts, the International Working Group (IWG) response criteria for myelodysplasia were updated. This retrospective analysis evaluated response to decitabine using updated IWG criteria in patients pooled from 2 decitabine trials. Patients and Methods: Outcomes for patients with myelodysplastic syndrome (MDS) with baseline marrow blasts ≥ 20% and < 30% (RAEB-t group) and < 20% (MDS group) were compared. Results: Patients with RAEB-t (n = 26) had a significantly shorter time from diagnosis to study treatment (7.3 vs. 18.3 months), a higher International Prognostic Scoring System (IPSS) risk (77% vs. 16% high-risk patients), and lower median baseline platelet count (62.3 vs. 112.7 × 103/μL) vs. patients with MDS (n = 157), yet no significant difference in overall response rate (ORR) (15.4% vs. 28.0%). Patients with MDS had better duration of response (9.9 vs. 5 months; P =.024) and overall survival (OS) (16.6 vs. 9.0 months; P =.021) compared with patients with RAEB-t. Conclusion: Decitabine is active in and may benefit patients with > 20% blasts (RAEB-t).

Original languageEnglish (US)
Pages (from-to)592-596
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number5
StatePublished - Oct 1 2013



  • Acute myeloid leukemia
  • FAB classification
  • Myelodysplastic syndrome
  • RAEB-t
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this